Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
1.
Can J Diabetes ; 46(3): 244-252, 2022 Apr.
Article in English | MEDLINE | ID: mdl-35568425

ABSTRACT

BACKGROUND: Patients with diabetes facing psychosocial challenges often struggle with diabetes self-management, and thereby are at risk of complications arising from hyperglycemia and hypoglycemia. Despite the Diabetes Canada Clinical Practice Guidelines' recommendations for diabetes centres to offer psychosocial services for the screening and support of patients with psychosocial barriers, the extent to which these recommendations have been implemented in centres across Canada is unknown. METHODS: Tertiary adult diabetes centres affiliated with academic institutions were invited to participate in our quantitative survey (n=40). At each centre, a structured telephone interview was administered to a manager, as well as a social worker and psychologist (if employed at the centre), to inquire regarding the psychosocial services offered. RESULTS: Thirty diabetes centres (75%) completed at least one questionnaire. Participating diabetes centres varied considerably in capacity, employing from 3 to more than 50 diabetes educators and from 0 to 20 endocrinologists. Approximately 80% of centres reported providing patients with access to psychosocial services, but only about 50% had a dedicated, internal psychosocial team. Stratified results showed centres that are the main centres affiliated with academic teaching hospitals were more likely to have embedded psychosocial services and to make referrals for psychosocial concerns when compared with satellite centres. The majority of managers reported that their staffing and funding model provided inadequate psychosocial support and that increased funding for psychosocial care was either somewhat of a priority or a high priority. CONCLUSIONS: Diabetes centres across Canada struggle to offer adequate psychosocial services; greater funding and training for staff is required to uphold the Diabetes Canada Clinical Practice Guidelines.


Subject(s)
Diabetes Mellitus , Hypoglycemia , Psychiatric Rehabilitation , Adult , Canada/epidemiology , Diabetes Mellitus/epidemiology , Diabetes Mellitus/therapy , Humans , Hypoglycemia/epidemiology , Hypoglycemia/prevention & control , Tertiary Care Centers
3.
Ear Nose Throat J ; 84(5): 290-2, 2005 May.
Article in English | MEDLINE | ID: mdl-15973784

ABSTRACT

To the best of our knowledge, only 3 cases of a simultaneous vestibular schwannoma and a glomus jugulare tumor have been previously reported in the literature. In all 3 cases, the lesions were located on the same side. We report a new case of simultaneous vestibular schwannoma and glomus jugulare tumor that is unique in that the two lesions arose on opposite sides. The glomus tumor was treated with embolization followed by radiotherapy, while the schwannoma was managed via radiologic observation.


Subject(s)
Glomus Jugulare Tumor/epidemiology , Neoplasms, Multiple Primary/epidemiology , Neuroma, Acoustic/epidemiology , Aged , Female , Glomus Jugulare Tumor/pathology , Humans , Magnetic Resonance Imaging , Neoplasms, Multiple Primary/pathology , Neuroma, Acoustic/pathology
4.
Surgery ; 133(3): 238-42, 2003 Mar.
Article in English | MEDLINE | ID: mdl-12660633

ABSTRACT

BACKGROUND: Intralesional injection of OK-432 has been proposed as an effective treatment of lymphangioma. The aim of this study was to review our experience with OK-432 injection of lymphangioma and to identify factors associated with successful outcome. METHODS: We made a case note review of 19 children who received OK-432 injection. Median duration of follow-up was 17 months. RESULTS: Lesions were diagnosed antenatally in 4 children, at birth in 4 children, and between 1 month and 11 years in the remainder. Anatomic locations were head/neck in 14, axilla in 1, and multiple locations in 4. Median number of injections per child was 2 (range, 1 to 5). Disappearance of the lesion was achieved after OK-432 injection in 2 patients (11%) and a marked reduction in 5 (26%); all these lesions were in the head and neck. Lesions larger than 5 cm and those outside the head and neck region did not respond well to OK-432 injection. Fourteen children (74%) required surgical excision after injection. Complications of OK-432 injection included partial tracheal obstruction, fever, local inflammatory response, and abscess formation. CONCLUSIONS: OK-432 injection was effective in approximately one third of children with lymphangioma. Lesions outside the head and neck and those larger than 5 cm are unlikely to respond to this therapy. Injection of lymphangioma surrounding the airways may be hazardous.


Subject(s)
Antineoplastic Agents/administration & dosage , Lymphangioma/drug therapy , Picibanil/administration & dosage , Child , Child, Preschool , Female , Follow-Up Studies , Humans , Infant , Infant, Newborn , Injections, Intralesional , Lymphangioma/surgery , Male , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL
...